A ge-related macular degeneration is the leading cause of blindness in industrialized nations, affecting >10 million Americans. The most severe form of macular degeneration, the "wet" form, is caused by growth of abnormal vessels that leak excessive fluid under the retina, damaging the macula and leading to loss of sharp, central, color vision. Vascular endothelial growth factor (VEGF) is a major factor that drives vasoproliferative diseases such as macular degeneration, and antibodies to VEGF are a mainstay of treatment. In this issue of Circulation, 1 Bucher and colleagues identify tetraspanin Tspan12 as a therapeutic target for retinal vascular proliferation, and they invent a Tspan12-targeting therapy.
The retinal vasculature is uniquely adapted to supply oxygen and nutrients to photoreceptor cells without blocking incoming light. However, these specialized features also make the retinal vasculature susceptible to vasoproliferative retinopathy, which is the aberrant growth of new blood vessels and breakdown of their barrier function. 2 Vasoproliferative retinopathies are driven by VEGF, a key regulator of physiological and pathological angiogenesis. VEGF production is driven primarily by the hypoxia-inducible factor family of transcription factors. VEGF stimulates angiogenesis by interacting with its receptors VEGFR1 and VEGFR2, which in turn activate intracellular signaling cascades such as the Ras-mitogen-activated protein kinase pathway, triggering endothelial migration and proliferation. VEGF-induced VEGFR2 signaling also increases vascular permeability by separating VE-cadherin complexes and intercellular adhesion junctions. The most effective treatment for vasoproliferative retinopathies is anti-VEGF therapy delivered by periodic intravitreal injections. However, the lack of response in some patients and relapses of neovascularization and edema between treatments indicate the clinical need for novel treatments. 2 In the current issue of Circulation, Bucher and colleagues 1 discovered that tetraspanin Tspan12 is a new therapeutic target for vasoproliferative retinopathies. The tetraspanins are a superfamily of 33 integral membrane with 4 transmembrane regions. Tetraspanins interact with specific partner proteins and regulate their intracellular trafficking or lateral diffusion and clustering at the cell surface. 3, 4 On endothelial cells, for example, tetraspanin CD151 is important for angiogenesis, potentially by promoting signaling through its laminin-binding integrin partner proteins. In addition, tetraspanins CD9, CD63, and CD151 promote leukocyte capture during inflammation by clustering and forming "sticky platforms" of the adhesion molecules intercellular adhesion molecule-1, P-selectin, and vascular cell adhesion molecule-1, respectively. 5 However, a substantial proportion of the 33 human tetraspanins have not been functionally characterized in terms of regulation of specific partner proteins at the molecular level. This is due in part to a lack of effective antibodies to these tetraspanins.
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In recent advances to the tetraspanin field, superresolution imaging has shown that tetraspanins exist as nanodomains on the cell surface that comprise clusters of ≈10 tetraspanins of a single type. 6 Moreover, the first full-length crystal structure of a tetraspanin, CD81, reported last year, 7 revealed a cone-shaped appearance with a cholesterol-binding cavity within the transmembrane regions (Figure) . Molecular dynamics simulations suggest that removal of the cholesterol may induce a striking conformational change in which the large extracellular region swings upward, providing a potential mechanism by which tetraspanins could regulate partner proteins by acting as molecular switches. 7 Although this is unproven and based on just 1 tetraspanin structure, it raises the exciting possibility that tetraspanins could be therapeutically targeted by small molecules that affect the cholesterol-binding cavity or antibodies/ small molecules that lock tetraspanins into a particular conformation.
In 2009, Junge and colleagues 8 reported the first characterization of Tspan12-deficient mice and showed Tspan12 to be important for the development of the retinal vasculature by promoting β-catenin signaling, an important pathway in embryonic development and in adult health and disease. At the molecular level, Tspan12 appears to promote multimerization of the Norrin receptor Frizzled 4 (FZD-4) 8 and interaction between FZD4 and its coreceptor low-density lipoprotein receptor-related protein 5 (LRP5) (Figure) . 9 In response to Norrin, the resulting intracellular signal stabilizes the multifunctional cytoplasmic protein β-catenin, which can then translocate to the nucleus to act as a transcriptional coactivator and turn on the expression of target genes 10 ( Figure) . On the basis of their observations in mice, Junge and colleagues speculated that mutations in human Tspan12, like existing mutations in FZD4, LRP5, and Norrin, might lead to the blinding disease familial exudative vitreoretinopathy. 8 This was proved correct a year later with the identification of disease-causing Tspan12 mutations. 11, 12 It is worth noting that Tspan12 expression in the retina is restricted to endothelial cells, 8 but in the rest of the body, expression is more widespread, and Tspan12 on epithelial cells and fibroblasts has been implicated in cancer progression via FZD4/LRP5-mediated β-catenin signaling. 9, 13 In the present study, Bucher and colleagues 1 aimed to generate anti-Tspan12 antibodies and to test whether they could reduce FZD4/LRP5-mediated β-catenin signaling and thus be used as a treatment for vasoproliferative retinopathy. Historically, attempts to generate new tetraspanin antibodies have often proved unsuccessful, possibly because of the small size of tetraspanins and high degree of protein sequence identity between human and mouse (98% for Tspan12). The approach by Bucher et al to this problem was novel and innovative. A 48-amino acid peptide encompassing the variable region of Tspan12 was generated and used as a target antigen. This variable region forms part of the large extracellular region, contains all 6 of the structurally important cysteine residues, is relatively divergent in sequence between tetraspanins, and typically mediates interactions with partner proteins. 3 A phage library of approximately 10 9 human antibodies was then screened against the peptide. This yielded 6 highaffinity antibodies. One of these was definitively shown to recognize full-length Tspan12 by flow cytometry and immunofluorescence microscopy, with Tspan12-overexpressing and Tspan12-knockdown cells used as key controls. 1 In the future, it will be interesting to determine whether this approach is applicable to other tetraspanins.
The chosen Tspan12 antibody was found to have only a modest inhibitory effect on primary human umbilical vein endothelial cell function in vitro when assays for migration and cell-cell adhesion were used. 1 However, β-catenin expression was substantially reduced by antibody treatment, suggesting inhibition of β-catenin signaling. The mechanism appears to involve disruption of Tspan12 interaction with FZD4, as measured by a modest reduction in coimmunoprecipitation of the proteins from transfected cells. 1 Although this is an artificial system, it may actually underrepresent the true disrupting effect of the Tspan12 antibody because much of the Tspan12-FZD4 complex may be intracellular and thus unaffected by antibody treatment. Tetraspanin antibody-mediated disruption of tetraspanin/ partner interactions is not without precedent in that a CD151 antibody can impair laminin-binding integrin function by disrupting the CD151-integrin interaction.
14 Nevertheless, to support the proposed mechanism of Tspan12 antibody action, future studies would benefit from fluorescence-based imaging methods that can measure protein-protein interactions in living cells in real time.
To investigate the therapeutic potential of their Tspan12 antibody, Bucher and colleagues 1 used 2 mouse vascular retinopathy models, the oxygen-induced retinopathy model and the very-low-density lipoprotein receptor knockout model. Oxygen-induced retinopathy is the most widely used model for disease of the inner retinal vasculature, through which light must pass to reach the photoreceptor cells. In this model, mice are subjected to 75% oxygen from 7 to 12 days of age, which suppresses VEGF expression in the retina with consequent loss of blood vessels. On re-exposure to normal air, the retina suffers relative hypoxia as a result of the lack of blood vessels. The resulting high-level expression of VEGF causes vessel overgrowth and characteristic vascular tufts that are maximal on day 17 of age, before it repairs during the following several days. In this model, intravitreal injection of Tspan12 antibody at day 12 of age reduced aberrant vessel overgrowth at day 17 by approximately one third while promoting recovery of the lost blood vessels. 1 Thus, the antibody modulates vessel growth rather than functioning as an antiangiogenic. The second model was the very-lowdensity lipoprotein receptor knockout mouse in which neovascular tufts develop from the outer retinal vessels that supply the overlying photoreceptor cells. Similar to its efficacy in the previous model, intravitreal injection of the Tspan12 antibody reduced neovascular tuft formation by approximately one third. 1 The gold-standard treatments for vascular retinopathies are anti-VEGF agents such as aflibercept, a clinically approved recombinant protein derived from VEGFR1 and VEGFR2 that neutralizes VEGF via high-affinity binding. In their concluding experiments, Bucher and colleagues 1 used the oxygen-induced retinopathy model to show that cotreatment with aflibercept and Tspan12 antibody doubled the efficacy of either treatment alone. Titration experiments further showed that relatively low-dose aflibercept, in combination with Tspan12 antibody, is an effective treatment without inducing the negative side effects on retinal function that are evident with higher doses of aflibercept. 1 In summary, this exciting study will be an "eye opener" for ophthalmologists, prompting clinical trials to assess anti-VEGF and Tspan12 antibody combination therapy for vascular retinopathies such as age-related macular degeneration and diabetic retinopathy. This study may also galvanize research into the molecular mechanism by which Tspan12 regulates FZD4 and, in particular, whether the recently proposed conformational change in tetraspanins could affect FZD4/LRP5-induced β-catenin signaling.
SOURCES OF FUNDING
Dr Tomlinson's research on tetraspanins in the vasculature is funded by a British Heart Foundation Project Grant (PG/13/92/30587) and PhD Studentship (FS/12/79/29871).
DISCLOSURES
None.
AFFILIATION
From School of Biosciences, College of Life and Environmental Sciences, University of Birmingham, United Kingdom.
FOOTNOTES
Circulation is available at http://circ.ahajournals.org.
